John Suffredini, DO
Interventional Cardiology · Houston, TXNPI 1235591389
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,637 of the $15,495 with a category attached, or 68.7%. 24 manufacturers reported payments, led by Abbott at 56.1% of the total. Reporting peaked in 2023 at $4,302 and has fallen 82.2% since, to $765 in 2025.
Across 191 payments — averaging $81.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Boston Scientific$2K
- Abiomed$1K
- Cardiovascular Systems Inc.$430
- Amgen$294
- Inari Medical, Inc.$284
- plus $2K from 18 others
What the payments were for
- Travel & lodging$4,32228%
- Food & beverage$10,63769%
- Education$5353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 92 | $8,693 |
| Boston Scientific | 14 | $2,001 |
| Abiomed | 17 | $1,476 |
| Cardiovascular Systems Inc. | 5 | $430 |
| Amgen | 10 | $294 |
| Inari Medical, Inc. | 2 | $284 |
| AstraZeneca | 6 | $254 |
| Philips North America LLC | 2 | $237 |
| Chiesi USA, Inc. | 7 | $183 |
| Elutia, Inc. | 1 | $167 |
| Johnson & Johnson | 4 | $151 |
| Medtronic(2 entities) | 4 | $150 |
| Shockwave Medical, Inc | 1 | $148 |
| Osprey Medical Inc | 1 | $144 |
| Teleflex LLC | 7 | $137 |
| GE HealthCare | 2 | $124 |
| Astellas Pharma US Inc | 2 | $123 |
| Novartis | 5 | $116 |
| Lundbeck LLC | 1 | $110 |
| Penumbra, Inc. | 1 | $96 |
| Pfizer | 4 | $65 |
| Cathworks, Inc. | 1 | $45 |
| Cardiva Medical, Inc. | 1 | $37 |
| Boehringer Ingelheim | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$2,889
- Impella$1,209
- Ensite Cardiac Mapping System$1,122
- CardioMEMS HF System$529
- CARDIOMEMS$426
- QUADRA ASSURA$356
- CT THROMBECTOMY SYSTEM KIT$284
- FLOWTRIEVER CATHETER, S$284
- iLab Ultrasound Imaging System$281
- Fortify Assura$178
- Quadra Assura CRT Defibrillator$172
- ECM Patch,Pouch$167
- Fortify Assura, Ellipse ICD$165
- GALLANT$163
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$148
- Diamondback Coronary$148
- DyeVert$144
- (7881) Ultrasound Und$125
- FARXIGA$124
- PERCLOSE PROGLIDE$117
How this compares
$15,495 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 19 | $14,249 |
| JardianceEmpagliflozin | 27 | $11,011 |
| EliquisApixaban | 21 | $7,183 |
| Metoprolol Succinate | 32 | $429 |
| Atorvastatin Calcium | 27 | $325 |
| ClopidogrelClopidogrel Bisulfate | 12 | $112 |
| Furosemide | 20 | $79 |
| Spironolactone | 17 | $67 |
| Carvedilol | 12 | $59 |
| Lisinopril | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $116 | $14,24919 claims |
| Boehringer IngelheimJardiance | $27 | $11,01127 claims |
| PfizerEliquis | $65 | $7,18321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.